We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now


It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

ELEV Elevation Oncology Inc

0.00 (0.0%)
Pre Market
Last Updated: 04:17:07
Delayed by 15 minutes


Draw Mode:

Volume 0
Bid Price 0.4573
Ask Price 0.6417
News -
Day High


52 Week Range


Day Low
Company Name Stock Ticker Symbol Market Type
Elevation Oncology Inc ELEV NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
0.00 0.0% 0.532 04:17:07
Open Price Low Price High Price Close Price Prev Close
Trades Volume Avg Volume 52 Week Range
0 0 - 0.363 - 5.89
Last Trade Time Type Quantity Stock Price Currency
- 0 $ 0.532 USD

Elevation Oncology Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
22.48M 42.41M - 0 -95.08M -2.24 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

Elevation Oncology News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No ELEV Message Board. Create One! See More Posts on ELEV Message Board See More Message Board Posts

Historical ELEV Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week0.46130.55260.46010.5093776112,8300.070715.33%
1 Month0.4450.55260.3630.4594626372,2080.08719.55%
3 Months0.710.7880.3630.5230601214,600-0.178-25.07%
6 Months4.264.3250.3631.49395,460-3.73-87.51%
1 Year0.905.890.3633.19723,882-0.368-40.89%
3 Years14.0016.220.3633.43392,157-13.47-96.2%
5 Years14.0016.220.3633.43392,157-13.47-96.2%

Elevation Oncology Description

Elevation Oncology Inc is an oncology company focused on the development of targeted therapeutics for the treatment of cancer in genomically defined patient populations. Its lead program is focused on neuregulin-1, or NRG1, fusions, which are rare genomic alterations that have the potential to be therapeutically actionable through targeted HER3 inhibition.

Your Recent History

Delayed Upgrade Clock

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

Support: 1-888-992-3836 |